Granted Patent B2

US 8,551,528 · App. 12/813,857 · Granted Oct 8, 2013

Abstract

Claims (19)

1. Diketopiperazine microparticles having a specific surface area of 40 m 2 /g to about 67 m 2 /g.

2. The diketopiperazine microparticles according to claim 1 , wherein said microparticles comprise a drug or active agent.

3. The diketopiperazine microparticles according to claim 2 , wherein said specific surface area is less than 62 m 2 /g.

4. The diketopiperazine microparticles according to claim 3 , wherein said drug or active agent is a peptide or protein.

5. The diketopiperazine microparticles according to claim 4 , wherein said peptide is an endocrine hormone.

6. The diketopiperazine microparticles according to claim 5 , wherein said endocrine hormone is insulin, parathyroid hormone, calcitonin, glucagon, glucagon-like peptide 1, oxyntomodulin, and an analog or active fragment of said endocrine hormone.

7. The diketopiperazine microparticles according to claim 1 , comprising (bis-3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine.

8. A dry powder comprising the diketopiperazine microparticles of claim 3 .

9. A composition comprising diketopiperazine microparticles having a specific surface area of 40 m 2 /g to about 67 m 2 /g.

10. The composition of claim 9 , wherein an active agent is present on a surface of the microparticles.

11. The composition of claim 10 , wherein the active agent is an endocrine hormone, a vasoactive agent, a neuroactive agent, a hormone, an anticoagulant, an immunomodulating agent, a cytotoxic agent, an antibiotic, an antiviral agent, an antigen, and infectious agent, an inflammatory mediator, a hormone, or a cell surface antigen.

12. The composition of claim 10 , wherein the active agent is insulin.

13. The composition of claim 12 , wherein the microparticles are about 11% insulin by weight.

14. The composition of claim 10 , wherein the active agent is GLP-1.

15. The composition of claim 10 , wherein the active agent is about 0.01% to about 20% of the weight of the microparticles.

16. The composition of claim 9 , wherein at least a portion of the microparticles are crystalline.

17. The composition of claim 9 , wherein the diketopiperazine microparticles comprise (bis-3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine; 2,5-diketo-3,6-di(4-succinylaminobutyl)piperazine; 2,5-diketo-3,6-di(4-glutarylaminobutyl) piperazine; or, 2,5-diketo-3,6-di(4-maleylaminobutyl)piperazine.

18. The composition of claim 9 , wherein the microparticles have a specific surface about 40 m 2 /g to about 62 m 2 /g.

19. The composition of claim 9 , wherein the microparticles comprise crystalline diketopiperazine that is formed by crystallization from an aqueous solution at a temperature of about 13° C. to about 23° C.

Assignments (8)